Analysts Set XOMA Corp (NASDAQ:XOMA) PT at $23.75

XOMA Corp (NASDAQ:XOMA) has been given a consensus rating of “Buy” by the seven brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $23.75.

A number of equities research analysts recently issued reports on XOMA shares. Wedbush set a $20.00 target price on Ares Capital and gave the company a “buy” rating in a research note on Tuesday, May 14th. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, HC Wainwright set a $30.00 target price on XOMA and gave the company a “buy” rating in a research note on Friday, June 14th.

In other XOMA news, insider Value Fund L. P. Biotechnology purchased 27,913 shares of XOMA stock in a transaction on Tuesday, May 14th. The shares were bought at an average price of $14.63 per share, with a total value of $408,367.19. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bvf Partners L. P/Il purchased 3,797 shares of XOMA stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $14.36 per share, for a total transaction of $54,524.92. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 42,010 shares of company stock worth $612,963. 9.89% of the stock is owned by corporate insiders.

Several institutional investors have recently modified their holdings of the business. California Public Employees Retirement System lifted its stake in shares of XOMA by 11.5% during the 4th quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,220 shares during the period. GSA Capital Partners LLP lifted its stake in shares of XOMA by 4.6% during the 4th quarter. GSA Capital Partners LLP now owns 57,415 shares of the biotechnology company’s stock worth $726,000 after purchasing an additional 2,500 shares during the period. Macquarie Group Ltd. lifted its stake in shares of XOMA by 4.8% during the 4th quarter. Macquarie Group Ltd. now owns 54,322 shares of the biotechnology company’s stock worth $687,000 after purchasing an additional 2,512 shares during the period. Smart Portfolios LLC purchased a new position in shares of XOMA during the 1st quarter worth $36,000. Finally, Two Sigma Advisers LP lifted its stake in shares of XOMA by 9.9% during the 4th quarter. Two Sigma Advisers LP now owns 32,195 shares of the biotechnology company’s stock worth $407,000 after purchasing an additional 2,905 shares during the period. 48.51% of the stock is currently owned by institutional investors.

Shares of NASDAQ:XOMA opened at $17.42 on Tuesday. The stock’s 50 day moving average price is $16.88. The company has a debt-to-equity ratio of 1.13, a quick ratio of 7.20 and a current ratio of 7.20. XOMA has a 12 month low of $11.02 and a 12 month high of $25.99.

XOMA (NASDAQ:XOMA) last posted its earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.33. XOMA had a negative return on equity of 51.66% and a negative net margin of 48.62%. The firm had revenue of $8.13 million for the quarter, compared to analyst estimates of $3.23 million. Analysts expect that XOMA will post -1.09 EPS for the current fiscal year.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Featured Story: How Do Mutual Funds Work?

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.